Blonde L, Raccah D, Lew E, Meyers J, Nikonova E, Ajmera M, Davis KL, Bertolini M, Guerci B. Treatment intensification in type 2 diabetes: a real world study of 2-OAD regimens, GLP-1 RAx, or basal insulin. Diabetes Ther. 2018 Jun;9(3):1169-84. doi: 10.1007/s13300-018-0429-x
Mansfield C, Sikirica MV, Pugh A, Poulos CM, Unmuessig V, Morano R, Martin AA. Patient preferences for attributes of type 2 diabetes mellitus medications in Germany and Spain: an online discrete-choice experiment survey. Diabetes Ther. 2017 Dec;8(6):1365-78. doi: 10.1007/s13300-017-0326-8
Poulos C, González JM, Lee LJ, Boye KS, Johnson FR, Bae JP, Deeg MA. Physician preferences for extra-glycemic effects of type 2 diabetes treatments. Diabetes Ther. 2013 Dec;4(2):443-59. doi: 10.1007/s13300-013-0046-7.
Loughlin J, Quinn S, Rivero E, Wong J, Huang J, Kralstein J. Tegaserod and the risk of cardiovascular ischemic events: an observational cohort study. J Cardiovasc Pharmacol. 2010 Jun;15(2):151-7.
Dubrey SW, Gnanasakthy A, Stein WK, Song JG, Hardman T, Hynd J, Noble MI. Enoximone in chronic stable angina: a double-blind placebo-controlled cross-over trial. J Cardiovasc Pharmacol. 1994 Apr;23(4):532-8.